alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.93    
  


 
 

EXTENSION AGREEMENT    
  


Bank
of America, N.A.,

as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 


Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 


        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	

 	
 	
Washington Mutual Bank
	

 	
 	

Name:	

/s/  ELIZABETH A. RECORDS      

	 	 	 	By:	Elizabeth A. Records

	 	 	 	Title:	Assistant Vice President, Credit Manager






	

Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	

/s/  BARRY EDWARDS      

	Name:	Barry Edwards

	Title:	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	

/s/  SUZANNE M. PAUL      

	Name:	Suzanne M. Paul

	Title:	Vice President












QuickLinks



Exhibit 10.93


EXTENSION AGREEMENT
Editorial Note on Part 886
Editorial Note: Nomenclature changes to part 886 appear at 73 FR 35341, June 23, 2008.

§ 886.1300 Afterimage flasher. ( a ) *Identification.* An afterimage flasher is an AC-powered light that automatically switches on and off to allow performance of an afterimage test in which the patient indicates the positions of afterimages after the light is off. The device is intended to determine harmonious/anomalous retinal correspondence (the condition in which corresponding points on the retina have the same directional value).
( b ) *Classification.* Class II.
[55 FR 48441, Nov. 20, 1990]
§ 876.5895 Ostomy irrigator. ( a ) *Identification.* An ostomy irrigator is a device that consists of a container for fluid, tubing with a cone-shaped tip or a soft and flexible catheter with a retention shield and that is used to wash out the colon through a colostomy, a surgically created opening of the colon on the surface of the body.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.
[48 FR 53023, Nov. 23, 1983, as amended at 84 FR 71814, Dec. 30, 2019]
QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.90    
  


 
 

EXTENSION AGREEMENT    
  


        March 5,
2002        


Bank
of America, N.A.,

    as Administrative Agent

Attn: Suzanne Paul

231 South LaSalle Street

Chicago, Illinois 60604 



Ladies
and Gentlemen: 


        The
undersigned hereby agrees to extend, effective April 3, 2002, its Commitment and the Maturity Date under the Credit Agreement dated as of April 3, 2001 among
SOURCECORP, Incorporated, f/k/a F.Y.I. Incorporated, each of the Lenders party thereto, Bank of America, N.A., as Administrative Agent, and Banc of America Securities LLC, as sole lead arranger and
sole book agent (as the same may be amended or otherwise modified from time to time, the "Credit Agreement") for 364 days to April 2, 2005
pursuant to Section 2.1(d) of the Credit Agreement. Terms defined in the Credit Agreement are used herein as therein defined. 



        This
Extension Agreement shall be construed in accordance with and governed by the law of the State of Texas. The Extension Agreement may be signed in any number of counterparts, each of
which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. 



	

 	
 	
THE BANK OF NOVA SCOTIA
	

 	
 	

Name:	

/s/ N. BELL

	 	 	 	By:	N. Bell

	 	 	 	Title:	Assistant Agent






	

Agreed and Accepted:
	

SOURCECORP, INCORPORATED, f/k/a

F.Y.I. INCORPORATED
	

By:	

/s/ BARRY EDWARDS

	Name:	Barry Edwards

	Title:	EVP & CFO

	

BANK OF AMERICA, N.A., as Administrative Agent
	

By:	

/s/ SUZANNE M. PAUL

	Name:	Suzanne M. Paul

	Title:	Vice President












QuickLinks



Exhibit 10.90


EXTENSION AGREEMENT
Editorial Note on Part 862
Editorial Note: Nomenclature changes to part 862 appear at 73 FR 35341, June 23, 2008.

§ 862.1785 Urinary urobilinogen (nonquantitative) test system. ( a ) *Identification.* A urinary urobilinogen (nonquantitative) test system is a device intended to detect and estimate urobilinogen (a bile pigment degradation product of red cell hemoglobin) in urine. Estimations obtained by this device are used in the diagnosis and treatment of liver diseases and hemolytic (red cells) disorders.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 862.9.
[52 FR 16122, May 1, 1987, as amended at 65 FR 2308, Jan. 14, 2000]
Michigan Supreme Court Lansing, Michigan

Marilyn Kelly,
Chief Justice

Michael F. Cavanag h
Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,
J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk March 25, 2009

p0318 

# Order

March 25, 2009

137273

SHEABRA L. SIMPSON, Ph.D., Plaintiff-Appellant,

v SC: 137273 COA: 275554 Wayne CC: 04-438895-CD DEPARTMENT OF CORR ECTIONS, JAN EPP, and HAMPTON E. WALKER, JR., Defendants-Appellees.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the May 27, 2008 judgment of the Court of Appeals is consid ered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.

K ELLY 

### , C.J., and H ATHAWAY



### , J., would grant leave to appeal.
Editorial Note on Part 868
Editorial Note: Nomenclature changes to part 868 appear at 73 FR 35341, June 23, 2008.

§ 868.1730 Oxygen uptake computer. ( a ) *Identification.* An oxygen uptake computer is a device intended to compute the amount of oxygen consumed by a patient and may include components for determining expired gas volume and composition.
( b ) *Classification.* Class II (performance standards).
§ 520.1242c Levamisol and piperazine. ( a ) *Specifications.* ( 1 ) Each ounce of solution contains 0.36 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 3.98 grams of piperazine base.
( 2 ) A soluble powder which when constituted with water contains in each fluid ounce 0.45 gram of levamisole hydrochloride and piperazine dihydrochloride equivalent to 5.0 grams of piperazine base.
( b ) *Sponsor.* See No. 054771 in § 510.600(c) of this chapter.
( c ) *Conditions of use in horses* — ( 1 ) *Amount.* Aqueous solution: administer by stomach tube or drench 1 fluid ounce per 100 pounds of body weight. Reconstituted soluble powder: administer by stomach tube 1 fluid ounce per 125 pounds of body weight. If reinfection occurs, re-treat animals at 6- to 8-week intervals.
( 2 ) *Indications for use.* An anthelmintic effective against infections of large strongyles (*Strongylus vulgaris, S. edentatus*), small strongyles (*Cylicocercus* spp., *Cylicocyclus* spp., *Cylicodontophorus* spp., *Cylicostephanus* spp., *Cylicotetrapedon* spp.), ascarids (*Parascaris equorum*), and pinworms (*Oxyuris equi*).
( 3 ) *Limitations.* Do not use in horses intended for human consumption. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[78 FR 28823, May 20, 2014]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.3360 Preformed cusp. ( a ) *Identification.* A performed cusp is a prefabricated device made of plastic or austenitic alloys or alloys containing 75 percent or greater gold and metals of the platinum group intended to be used as a temporary cusp (a projection on the chewing surface of a tooth) to achieve occlusal harmony (a proper bite) before permanent restoration of a tooth.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 59 FR 63008, Dec. 7, 1994; 66 FR 38798, July 25, 2001]
Exhibit 31.a

I, John P. Manning, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Affordable Housing II Limited Partnership;
2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



1. designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
2. evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
3. disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and





1. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):



1. all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
2. any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.





|Date: August 20, 2007 | /s/ John P. Manning        
|--------------------- | ---------------------------
|                      | John P. Manning            
|                      | Principal Executive Officer
|                      |                            
|                      |                            
|                      |
§ 861.24 Existing standard as a proposed standard. ( a ) The Food and Drug Administration may accept an existing standard or a proposed or draft standard if it includes: ( 1 ) A description of the procedures used to develop the standard and a list of the persons and organizations that participated in its development, to the extent that such information is available or reasonably obtainable;
( 2 ) An identification of the specific portions of the existing standard that the person submitting the standard believes are appropriate for adoption as, or inclusion in, the proposed standard; and
( 3 ) A summary of the test data, or, if requested by the Food and Drug Administration, all such data or other information supporting the specific portions of the standard identified by the person submitting the standard.
( b ) The Food and Drug Administration will publish a notice in the Federal Register stating either that it has accepted, or accepted with modification, as a proposed standard, an existing standard or one that has been developed, or that an existing standard is not acceptable, together with the reasons therefor.
[45 FR 7484, Feb. 1, 1980, as amended at 57 FR 58405, Dec. 10, 1992]
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.2400 Bed-patient monitor. ( a ) *Identification.* A bed-patient monitor is a battery-powered device placed under a mattress and used to indicate by an alarm or other signal when a patient attempts to leave the bed.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 59 FR 63010, Dec. 7, 1994; 66 FR 38803, July 25, 2001]
I 

118TH CONGRESS 

2D SESSION H. R. 7988 

To amend the Small Business Act to include requirements relating to new 

small business entrants in the scorecard program, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

APRIL 15, 2024 

Mr. STAUBER (for himself and Ms. PEREZ) introduced the following bill; 

which was referred to the Committee on Small Business 

A BILL 

To amend the Small Business Act to include requirements 

relating to new small business entrants in the scorecard 

program, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Small Business Pro5 curement and Utilization Reform Act of 2024’’ or the 

6 ‘‘SPUR Act’’. 

7 SEC. 2. MODIFICATIONS TO SCORECARD REQUIREMENTS. 

8 Section 15(y) of the Small Business Act (15 U.S.C. 

9 644(y)) is amended— 

10 (1) in paragraph (2)— 


ssavage on LAPJG3WLY3PROD with BILLS
2 

•HR 7988 IH

1 (A) by redesignating subparagraph (E) as 

2 subparagraph (F); and 

3 (B) by inserting after subparagraph (D) 

4 the following new subparagraph: 

5 ‘‘(E) The number of new small business 

6 entrants, including new small business entrants 

7 that are small business concerns owned and 

8 controlled by service-disabled veterans, qualified 

9 HUBZone small business concerns, small busi10 ness concerns owned and controlled by socially 

11 and economically disadvantaged individuals, and 

12 small business concerns owned and controlled 

13 by women awarded prime contracts in each 

14 North American Industry Classification System 

15 code during the fiscal year, and a comparison 

16 to the number awarded prime contracts during 

17 the prior fiscal year, if available.’’; 

18 (2) in paragraph (3), by striking ‘‘subpara19 graphs (B) through (E) of paragraph (2)’’ and in20 serting ‘‘subparagraphs (B) through (F) of para21 graph (2)’’; and 

22 (3) by amending paragraph (6) to read as fol23 lows: 

24 ‘‘(6) DEFINITIONS.—In this subsection: 


ssavage on LAPJG3WLY3PROD with BILLS
3 

•HR 7988 IH

1 ‘‘(A) NEW SMALL BUSINESS ENTRANT.— 

2 The term ‘new small business entrant’ means a 

3 small business concern that— 

4 ‘‘(i) has been awarded a prime con5 tract; and 

6 ‘‘(ii) has not previously been awarded 

7 a prime contract by the Federal Govern8 ment. 

9 ‘‘(B) SCORECARD.—The term ‘scorecard’ 

10 means any summary using a rating system to 

11 evaluate the efforts of a Federal agency to meet 

12 goals established under subsection (g)(1)(B) 

13 that— 

14 ‘‘(i) includes the measures described 

15 in paragraph (2); and 

16 ‘‘(ii) assigns a score to each Federal 

17 agency evaluated.’’. 

18 SEC. 3. COMPLIANCE WITH CUTGO. 

19 No additional amounts are authorized to be appro20 priated to carry out this Act or the amendments made 

21 by this Act. 

Æ 


ssavage on LAPJG3WLY3PROD with BILLS
Editorial Note on Part 882
Editorial Note: Nomenclature changes to part 882 appear at 73 FR 35341, June 23, 2008.

§ 882.5360 Cranioplasty plate fastener. ( a ) *Identification.* A cranioplasty plate fastener is a screw, wire, or other article made of tantalum, vitallium, or stainless steel used to secure a plate to the patient's skull to repair a skull defect.
( b ) *Classification.* Class II (performance standards).
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5420 Pressure infusor for an I.V. bag. ( a ) *Identification.* A pressure infusor for an I.V. bag is a device consisting of an inflatable cuff which is placed around an I.V. bag. When the device is inflated, it increases the pressure on the I.V. bag to assist the infusion of the fluid.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 65 FR 2318, Jan. 14, 2000]
Editorial Note on Part 872
Editorial Note: Nomenclature changes to part 872 appear at 73 FR 35341, June 23, 2008.

§ 872.6100 Anesthetic warmer. ( a ) *Identification.* An anesthetic warmer is an AC-powered device into which tubes containing anesthetic solution are intended to be placed to warm them prior to administration of the anesthetic.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 872.9.
[52 FR 30097, Aug. 12, 1987, as amended at 60 FR 38900, July 28, 1995; 66 FR 38799, July 25, 2001]
Editorial Note on Part 892
Editorial Note: Nomenclature changes to part 892 appear at 73 FR 35341, June 23, 2008.

§ 892.5725 Absorbable perirectal spacer. ( a ) *Identification.* An absorbable perirectal spacer is composed of biodegradable material that temporarily positions the anterior rectal wall away from the prostate during radiotherapy for prostate cancer with the intent to reduce the radiation dose delivered to the anterior rectum. The absorbable spacer maintains space for the entire course of prostate radiotherapy treatment and is completely absorbed by the patient's body over time.
( b ) *Classification.* Class II (special controls). The special controls for this device are: ( 1 ) The premarket notification submission must include methodology and results of the following non-clinical and clinical performance testing. For all clinical investigations used to support premarket notification submissions for this type of device, line listings of the study data must be provided. ( i ) Performance bench testing must demonstrate appropriate perirectal space creation and maintenance for the duration of prostate radiotherapy.
( ii ) Performance bench testing must demonstrate that therapeutic radiation levels do not alter the performance of the device.
( iii ) Performance in vivo testing must demonstrate appropriate deployment of spacer as indicated in the accompanying labeling, and demonstrate appropriate expansion and absorption characteristics in a clinically relevant environment.
( iv ) Clinical study must demonstrate appropriate spacer stability and lack of migration for the entire course of radiotherapy, complete absorption, and lack of long term toxicity.
( v ) Sterility testing must demonstrate the sterility of the device and the effects of the sterilization process on the physical characteristics of the spacer.
( vi ) Shelf-life testing must demonstrate the stability of the physical characteristics of the spacer throughout the shelf-life as indicated in the accompanying labeling.
( vii ) The device must be demonstrated to be biocompatible.
( 2 ) The risk management activities performed as part of the manufacturer's § 820.30 design controls must document an appropriate end user initial training program which will be offered as part of efforts to mitigate the risk of failure to correctly operate the device, including, but not limited to, documentation of an appropriate end user initial training program on the proper spacer deployment technique.
( 3 ) The device labeling must include the following: ( i ) A detailed summary of reported or observed complications related to the use of the device;
( ii ) Appropriate warnings;
( iii ) Detailed instructions for system preparations and detailed implant procedure instructions; and
( iv ) An expiration date that is supported by performance data as specified in paragraph (b)(1)(vi) of this section.
[83 FR 601, Jan. 5, 2018]
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7805 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7805

To amend the Immigration and Nationality Act with respect to the right 
of members of a federally recognized Indian Tribe in the United States 
  and First Nations individuals in Canada to cross the borders of the 
  United States and to be considered lawfully admitted for permanent 
                               residence.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 22, 2024

Mr. Kilmer (for himself, Mr. Fulcher, and Mrs. Peltola) introduced the 
  following bill; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
To amend the Immigration and Nationality Act with respect to the right 
of members of a federally recognized Indian Tribe in the United States 
  and First Nations individuals in Canada to cross the borders of the 
  United States and to be considered lawfully admitted for permanent 
                               residence.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Tribal Border Crossing Parity Act''.

SEC. 2. MEMBERS OF A FEDERALLY RECOGNIZED INDIAN TRIBE IN THE UNITED 
              STATES OR A FIRST NATION IN CANADA.

    Section 289 of the Immigration and Nationality Act (8 U.S.C. 1359) 
is amended--
            (1) by inserting ``(a)'' before ``Nothing'';
            (2) by striking ``who possess at least 50 per centum of 
        blood of the American Indian race.'' and inserting the 
        following: ``who--
            ``(1) are members, or are eligible to become members, of a 
        federally recognized Indian Tribe in the United States; or
            ``(2)(A) has Indian status in Canada through registration 
        under the Indian Act (R.S.C., 1985, c. I-5); or
            ``(B) holds membership in a self-governing First Nation in 
        Canada.'';
 and
            (3) by adding at the end the following:
    ``(b) An individual who is admitted to the United States pursuant 
to subsection (a) shall have the status of an alien lawfully admitted 
for permanent residence.''.
                                 <all>
```